Tag: Bria-OTS™

March 26, 2020

BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

BriaCell Therapeutics announces that the Phase I/IIa clinical study of Bria-IMT™ with Incyte Corporation’s immune checkpoint inhibitor, is ongoing.
February 26, 2020

BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting

BriaCell has been selected to present at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San...
February 11, 2020

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

BriaCell Therapeutics Corp. announced that Dr. Saveri Bhattacharya has been selected to receive support from the Merck Investigator Studies Program.
January 28, 2020

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

BriaCell is pleased to announce that the data of its clinical studies will be presented the at the Annual Symposium...
January 22, 2020

BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

BriaCell announced that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine...
January 13, 2020

BriaCell Provides Update on Remarkable Responder

BriaCell is pleased to provide an update on the top responder in the combination study of Bria-IMT™, with Incyte’s INCMGA00012,...
January 9, 2020

BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade

BriaCell is pleased to announce it has identified a new group of patients with high levels of clinical benefit in...